

Notification of forthcoming release of securities subject to voluntary escrow

Sydney, Australia, Wednesday, 1 April 2020: Next Science Limited (ASX:NXS) (**Next Science**), advises, in accordance with Listing Rule 3.10A, that the following Next Science securities will be released from voluntary escrow on 20 April 2020:

- 39,173,525 fully paid ordinary shares (quoted); and
- 650,000 partly paid ordinary shares (unquoted).

The shares detailed above have been subject to voluntary escrow since 18 April 2019, the date of commencement of quotation of Next Science's ordinary fully paid shares.

Approved by Next Science's Board of Directors.

Further information:

Judith Mitchell, Managing Director

Phone: +61 2 8607 5124

Email: investorqueries@nextscience.com

Michael Brown

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com.